CDNA microarray analysis of the effect of cantharidin on DNA damage, cell cycle and apoptosis-associated gene expression in NCI-H460 human lung cancer cells in vitro

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 1030-1042

  Hsia, Te Chun ^a,b   Yu, Chien Chih ^a   Hsu, Shu Chun ^a   Tang, Nou Ying ^a   Lu, Hsu Feng ^c   Yu, Chun Shu ^a   Wu, Shin Hwar ^d   Lin, Jaung Geng ^a   Chung, Jing Gung ^a,e  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e ASIA UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Cantharidin; Cell cycle; DNA damage; H460 cells; In vitro

Indexed keywords

CANTHARIDIN; CARD6 PROTEIN; COMPLEMENTARY DNA; CYCLIN D2; CYCLINE DEPENDENT KINASE LIKE 3; DNIT3 PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45A; PROTEIN; PROTEIN CDC42EP3; RAS P21 PROTEIN ACTIVATOR 4; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CCND2 PROTEIN, HUMAN; CDKL3 PROTEIN, HUMAN; CELL CYCLE PROTEIN; DDIT4 PROTEIN, HUMAN; ENZYME INHIBITOR; GADD45A PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE; RASA4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG EXPOSURE; GENE EXPRESSION; GENE ONTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; LUNG CANCER CELL LINE; MICROARRAY ANALYSIS; NCI H460 CELL LINE; UPREGULATION; DNA MICROARRAY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NON SMALL CELL LUNG CANCER; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CANTHARIDIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN D2; DNA DAMAGE; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ONTOLOGY; HUMANS; MICROARRAY ANALYSIS; MOLECULAR SEQUENCE ANNOTATION; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; RAS GTPASE-ACTIVATING PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84926661483     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3538     Document Type: Article

References (32)

1. Bilello KS, Murin S and Matthay RA: Epidemiology, etiology, and prevention of lung cancer. Clin Chest Med 23: 1-25, 2002.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
3. Zhang P, Gao WY, Turner S and Ducatman BS: Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2: 1, 2003.
4. Midthun DE and Jett JR: Chemotherapy for advanced lung cancer. When to expect a response. Postgrad Med 101: 187-194, 1997.
5. Stewart DJ: Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 75: 173-234, 2010.
6. Chansky K, Sculier JP, Crowley JJ, et al; International Staging Committee and Participating Institutions: The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4: 792-801, 2009.
7. Zhang W, Ma YZ, Song L, Wang CH, Qi TG and Shao GR: Effect of cantharidins in chemotherapy for hepatoma: A retrospective cohort study. Am J Chin Med 42: 561-567, 2014.
8. Dorn DC, Kou CA, Png KJ and Moore MA: The effect of cantharidins on leukemic stem cells. Int J Cancer 124: 2186-2199, 2009.
9. Huh JE, Kang KS, Chae C, Kim HM, Ahn KS and Kim SH: Roles of p38 and JNK mitogen-activated protein kinase pathways during cantharidin-induced apoptosis in U937 cells. Biochem Pharmacol 67: 1811-1818, 2004.
10. Li W, Xie L, Chen Z, et al: Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Sci 101: 1226-1233, 2010.
11. Yeh CB, Su CJ, Hwang JM and Chou MC: Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells. Eur J Med Chem 45: 3981-3985, 2010.
12. Chang C, Zhu YQ, Mei JJ, Liu SQ and Luo J: Involvement of mitochondrial pathway in NCTD-induced cytotoxicity in human hepG2 cells. J Exp Clin Cancer Res 29: 145, 2010.
13. Huang WW, Ko SW, Tsai HY, et al: Cantharidin induces G2/M phase arrest and apoptosis in human colorectal cancer colo 205 cells through inhibition of CDK1 activity and caspase-dependent signaling pathways. Int J Oncol 38: 1067-1073, 2011.
14. Zhang WD, Zhao HR, Yan Y, Wang XH, Zong ZH and Liu Y: Apoptosis induced by cantharidin in human pulmonary carcinoma cells A549 and its molecular mechanisms. Zhonghua Zhong Liu Za Zhi 27: 330-334, 2005 (In Chinese).
15. Kim JA, Kim Y, Kwon BM and Han DC: The natural compound cantharidin induces cancer cell death through inhibition of heat shock protein 70 (HSP70) and Bcl-2-associated athanogene domain 3 (BAG3) expression by blocking heat shock factor 1 (HSF1) binding to promoters. J Biol Chem 288: 28713-28726, 2013.
16. Osborne C, Wilson P and Tripathy D: Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 9: 361-377, 2004.
17. Heneghan HM, Miller N and Kerin MJ: MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol 10: 543-550, 2010.
18. Weinstein IB: Cancer. Addiction to oncogenes-The Achilles heal of cancer. Science 297: 63-64, 2002.
19. Luo J, Solimini NL and Elledge SJ: Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823-837, 2009.
20. Solimini NL, Luo J and Elledge SJ: Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130: 986-988, 2007.
21. Méndez M, Custodio A and Provencio M: New molecular targeted therapies for advanced non-small cell lung cancer. J Thorac Dis 3: 30-56, 2011.
22. Chang YM, Velmurugan BK, Kuo WW, et al: Inhibitory effect of alpinate Oxyphyllae fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cells. BioMedicine 3: 148-152, 2013.
23. Hsia TC, Yu CC, Hsu SC, et al: Cantharidin induces apoptosis of H460 human lung cancer cells through mitochondria-dependent pathways. Int J Oncol 45: 245-254, 2014.
24. Ayala F, Dewar R, Kieran M and Kalluri R: Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 23: 2233-2241, 2009.
25. Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487: 500-504, 2012.
26. Wilson TR, Fridlyand J, Yan Y, et al: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487: 505-509, 2012.
27. Moniri MR, Dai LJ and Warnock GL: The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchynmal stem cells. Cancer Gene Ther 21: 12-23, 2014.
28. Pignon JP, Tribodet H, Sagliotti GV, et al; LACE Collaborative Group: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26: 3552-3559, 2008.
29. Pepe C, Hasan B, Winton TL, et al; National Cancer Institute of Canada and Intergroup Study FBR.10: Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 25: 1553-1561, 2007.
30. Glynne-Jones R and Hoskin P: Neoadjuvant cisplatin chemotherapy before chemoradiation: A flawed paradigm? J Clin Oncol 25: 5281-5286, 2007.
31. Ricci MS and Zong WX: Chemotherapeutic approaches for targeting cell death pathways. Oncologist 11: 342-357, 2006.
32. Tan TT and White E: Therapeutic targeting of death pathways in cancer: Mechanisms for activating cell death in cancer cells. Adv Exp Med Biol 615: 81-104, 2008.